Cyrus Harmon - Aug 16, 2023 Form 4/A - Amendment Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Aug 16, 2023
Transactions value $
-$152,100
Form type
4/A - Amendment
Date filed
9/5/2023, 04:05 PM
Date Of Original Report
Aug 17, 2023
Previous filing
Jun 9, 2023
Next filing
Sep 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$152K -15K -1.44% $10.14 1.02M Aug 16, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
F2 On August 17, 2023, the reporting person filed a Form 4 that inadvertently excluded the weighted average sale price for the transaction. This amendment is being filed solely to report that the weighted average sale price for the transaction reported was $10.14, and the range of prices were between $9.765 and $10.65. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.